

Francesco Trotta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/904381/publications.pdf>

Version: 2024-02-01

65
papers

1,652
citations

279701

23
h-index

302012

39
g-index

71
all docs

71
docs citations

71
times ranked

2654
citing authors

#	ARTICLE	IF	CITATIONS
1	Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014-2019. <i>Frontiers in Medicine</i> , 2022, 9, 820757.	1.2	5
2	Monitoring the community use of antibiotics in Italy within the National Action Plan on antimicrobial resistance. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1033-1042.	1.1	16
3	Trends in hip and distal femoral fracture rates in Italy from 2007 to 2017. <i>Bone</i> , 2021, 142, 115752.	1.4	11
4	Real world data to identify target population for new CAR-T therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 78-85.	0.9	4
5	Variables affecting pricing of orphan drugs: the Italian case. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 439.	1.2	6
6	The Italian Network for Monitoring Medication Use During Pregnancy (MoM-Net): Experience and Perspectives. <i>Frontiers in Pharmacology</i> , 2021, 12, 699062.	1.6	1
7	The Assessment of the Innovativeness of a New Medicine in Italy. <i>Frontiers in Medicine</i> , 2021, 8, 793640.	1.2	5
8	In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study. <i>BioDrugs</i> , 2020, 34, 55-64.	2.2	2
9	Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy. <i>Drug Safety</i> , 2020, 43, 1-5.	1.4	10
10	Using GRADE methodology to assess innovation of new medicinal products in Italy. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 93-105.	1.1	18
11	How medicines are used in Italy: Data from the National Report 2018. <i>Health Policy and Technology</i> , 2020, 9, 32-38.	1.3	4
12	How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 195-199.	0.8	3
13	Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study. <i>Drug Safety</i> , 2019, 42, 1437-1447.	1.4	19
14	Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency. <i>Health Policy</i> , 2019, 123, 595-600.	1.4	30
15	Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. <i>BMJ Open</i> , 2019, 9, e033728.	0.8	17
16	Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis. <i>Journal of Nephrology</i> , 2018, 31, 321-332.	0.9	15
17	Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 738-763.	1.1	3
18	Comparative Effectiveness of Two Tiotropium Formulations: A Retrospective Cohort Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018, 15, 418-423.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Neonatal outcomes following new reimbursement limitations on palivizumab in Italy. Archives of Disease in Childhood, 2018, 103, 1163-1167.	1.0	8
20	Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. Clinical Epidemiology, 2018, Volume 10, 203-213.	1.5	12
21	Studies on drug switchability showed heterogeneity in methodological approaches: a scoping review. Journal of Clinical Epidemiology, 2018, 101, 5-16.	2.4	2
22	Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009-2014. Frontiers in Endocrinology, 2018, 9, 95.	1.5	17
23	Information needs on precision medicine: a survey of Italian health care professionals. Annali Dell'Istituto Superiore Di Sanita, 2018, 54, 316-323.	0.2	2
24	Kawasaki disease and immunisation: A systematic review. Vaccine, 2017, 35, 1770-1779.	1.7	27
25	Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy. BMJ Open, 2017, 7, e011637.	0.8	22
26	Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region. BioDrugs, 2017, 31, 117-124.	2.2	16
27	Qual È il Giusto Place in Therapy Dell'olmesartan?. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000264.	0.2	0
28	Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study. PLoS ONE, 2017, 12, e0176276.	1.1	6
29	Intussusception hospitalizations incidence in the pediatric population in Italy: a nationwide cross-sectional study. Italian Journal of Pediatrics, 2016, 42, 89.	1.0	10
30	Single organ cutaneous vasculitis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2016, 34, 6561-6571.	1.7	6
31	Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2016, 34, 6015-6026.	1.7	74
32	Italian program for independent research on drugs: 10-year follow-up of funded studies in the area of rare diseases. Orphanet Journal of Rare Diseases, 2016, 11, 36.	1.2	3
33	Vasculitis as an adverse event following immunization - Systematic literature review. Vaccine, 2016, 34, 6641-6651.	1.7	87
34	Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. Vaccine, 2016, 34, 6634-6640.	1.7	41
35	Kounis Syndrome: An analysis of spontaneous reports from international pharmacovigilance database. International Journal of Cardiology, 2016, 203, 217-220.	0.8	36
36	Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study. BMJ Open, 2015, 5, e006619-e006619.	0.8	6

#	ARTICLE	IF	CITATIONS
37	A Multicentric Prospective Incidence Study of Guillain-Barré Syndrome in Italy. The ITANG Study. <i>Neuroepidemiology</i> , 2015, 45, 90-99.	1.1	27
38	Ongoing pharmacovigilance on vaccines. <i>Pharmacological Research</i> , 2015, 92, 2-5.	3.1	8
39	Antihypertensive drug use during pregnancy: a population based study. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2015, 51, 236-43.	0.2	3
40	How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views. <i>Annals of Oncology</i> , 2014, 25, 265-269.	0.6	36
41	Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort study. <i>BMJ</i> , The, 2014, 348, g3361-g3361.	3.0	38
42	Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9578-9597.	2.9	46
43	Vaccine effectiveness against severe laboratory-confirmed influenza in children: Results of two consecutive seasons in Italy. <i>Vaccine</i> , 2014, 32, 4466-4470.	1.7	17
44	Generic substitution of antidiabetic drugs in the elderly does not affect adherence. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2014, 50, 333-40.	0.2	4
45	Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination. <i>European Journal of Epidemiology</i> , 2013, 28, 433-444.	2.5	41
46	The incidence of narcolepsy in Europe: Before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. <i>Vaccine</i> , 2013, 31, 1246-1254.	1.7	205
47	Drug use and upper gastrointestinal complications in children: a case-control study. <i>Archives of Disease in Childhood</i> , 2013, 98, 218-221.	1.0	32
48	Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparency. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1149-1151.	1.1	14
49	Stevens-Johnson Syndrome Associated with Drugs and Vaccines in Children: A Case-Control Study. <i>PLoS ONE</i> , 2013, 8, e68231.	1.1	29
50	Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice. <i>Journal of Clinical Oncology</i> , 2011, 29, 2266-2272.	0.8	64
51	Effectiveness and safety of the A-H1N1 vaccine in children: a hospital-based case-control study. <i>BMJ Open</i> , 2011, 1, e000167-e000167.	0.8	10
52	Discovery of Bishomo(hetero)arylpiperazines as Novel Multifunctional Ligands Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4803-4807.	2.9	25
53	Feasibility and challenges of independent research on drugs: the Italian Medicines Agency (AIFA) experience. <i>European Journal of Clinical Investigation</i> , 2010, 40, 69-86.	1.7	49
54	Therapeutic indications in oncology: Emerging features and regulatory dynamics. <i>European Journal of Cancer</i> , 2010, 46, 471-475.	1.3	5

#	ARTICLE	IF	CITATIONS
55	Off-label use of medicines in children: can available evidence avoid useless paediatric trials?. European Journal of Clinical Pharmacology, 2009, 65, 209-216.	0.8	40
56	In reply to: Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children. European Journal of Clinical Pharmacology, 2009, 65, 851-852.	0.8	17
57	Discovery of a New Class of Potential Multifunctional Atypical Antipsychotic Agents Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors: Design, Synthesis, and Effects on Behavior. Journal of Medicinal Chemistry, 2009, 52, 151-169.	2.9	79
58	A new anti-cancer drug in the market: Good news for investors or for patients?. European Journal of Cancer, 2008, 44, 1786-1788.	1.3	16
59	1H-Cyclopentapyrimidine-2,4(1H,3H)-dione-Related Ionotropic Glutamate Receptors Ligands. Structure-Activity Relationships and Identification of Potent and Selective iGluR5 Modulators. Journal of Medicinal Chemistry, 2008, 51, 6614-6618.	2.9	22
60	Stopping a trial early in oncology: for patients or for industry?. Annals of Oncology, 2008, 19, 1347-1353.	0.6	44
61	Haematological anticancer drugs in Europe: any added value at the time of approval?. European Journal of Clinical Pharmacology, 2007, 63, 713-719.	0.8	17
62	Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. International Clinical Psychopharmacology, 2006, 21, 319-336.	0.9	84
63	Novel Atypical Antipsychotic Agents: A Rational Design, an Efficient Palladium-Catalyzed Route, and Pharmacological Studies. Journal of Medicinal Chemistry, 2005, 48, 1705-1708.	2.9	37
64	Synthesis and Pharmacological Evaluation of Potent and Highly Selective D3 Receptor Ligands: Inhibition of Cocaine-Seeking Behavior and the Role of Dopamine D3/D2 Receptors. Journal of Medicinal Chemistry, 2003, 46, 3822-3839.	2.9	90
65	How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?. Therapeutic Innovation and Regulatory Science, 0, , 216847901882088.	0.8	1